North & Central America

This archive covers progress stories from North and Central America, spanning the U.S., Canada, Mexico, and the nations of Central America. Readers will find reporting on health, environment, community resilience, and policy advances across the region.

A medical professional preparing an injectable syringe for an article about lenacapavir HIV prevention, for article on annual HIV injection

Annual jab for HIV protection passes trial hurdle

By / / Good News For Humankind

A once-yearly HIV prevention shot has just cleared its first safety trial, with the drug lenacapavir still detectable in participants’ bodies a full 56 weeks after a single injection. That’s a hopeful sign for people who find daily prevention pills hard to maintain — whether because of stigma, unstable housing, or simply the grind of remembering. Earlier trials of twice-yearly lenacapavir already showed striking results, and researchers are now testing whether one shot a year could work just as well. With nearly 40 million people living with HIV globally, a prevention tool this simple could reshape what protection looks like — especially for communities where daily medication has never been realistic.

Monarch butterfly, for article on monarch butterfly population, for article on monarch butterfly population

Eastern monarch butterfly population nearly doubles in 2025

By / / Good News For Humankind

Monarch butterflies are bouncing back: this past winter, the eastern population blanketed 4.42 acres of Mexican highland forest, nearly double the area recorded a year earlier. Scientists credit milder drought along the migration route, but they also point to the people doing the quiet, daily work — Indigenous and rural communities in the Monarch Butterfly Biosphere Reserve who patrol against illegal logging, monitor habitat, and run ecotourism that ties their livelihoods to the butterflies’ return. It’s a fragile gain, not a finish line, since the long-term average remains much higher. Still, this rebound is a reminder that cross-border conservation can work — and that protecting a 3,000-mile migration takes all of us, everywhere along the way.

Two people holding hands, for article on Parkinson's infusion device, for article on Onapgo approval

U.S. approves “milestone” Parkinson’s treatment for 2025 release

By / / Good News For Humankind

Onapgo, a new wearable approved by the FDA, will give Americans with Parkinson’s a continuous, non-surgical way to manage their symptoms when it launches in late 2025. The small device delivers a steady infusion of apomorphine under the skin, bypassing the digestive system entirely — a real advantage for a disease that often slows digestion and makes pills unpredictable. In trials, patients cut their daily “off” episodes — those rough stretches when medication wears off and tremors return — by nearly two and a half hours on average. The therapy has quietly helped European patients for about three decades, and its U.S. arrival opens a gentler path for the roughly one million Americans living with Parkinson’s, part of a growing global push toward more humane, individualized care.

A doctor reviewing a prescription pad in a clinical setting for an article about non-opioid pain drug approval

FDA approves first non-opioid pain drug in more than 20 years

By / / Good News For Humankind

The FDA’s approval of Journavx (suzetrigine), a first-in-class non-opioid pain drug, marks the most significant shift in acute pain treatment in over two decades. Developed by Vertex Pharmaceuticals, the drug blocks a specific sodium channel in the peripheral nervous system, stopping pain signals before they reach the brain without engaging the opioid pathways linked to addiction and overdose. Two rigorous clinical trials confirmed its effectiveness for moderate to severe acute pain. With more than 500,000 opioid overdose deaths in the U.S. since 1999, this approval offers patients and doctors a genuinely new choice — one that treats real pain without the shadow of dependence.

A heat pump unit on a home exterior, representing U.S. heat pump sales growth supported by the Kigali Amendment, for article on heat pump agreement

Heat pumps outsell gas furnaces in the U.S. for the second year running

By / / Good News For Humankind

Heat pump sales have now surpassed gas furnace shipments in the United States for two consecutive years, with more than 4 million units sold in 2023 alone — a milestone that is beginning to look like a permanent market shift. Driven by federal tax credits under the Inflation Reduction Act and additional state-level rebates, Americans are increasingly choosing electric heating over fossil fuels. This matters because home heating accounts for roughly 10% of U.S. greenhouse gas emissions, and unlike gas furnaces, heat pumps grow cleaner automatically as the electrical grid adds more renewable energy. The two-year streak signals that economics, policy, and technology have aligned in ways that rarely reverse.

Karla Sofia Gascón at 2024 Cannes Film Festival, for article on trans actor Oscar nomination

Karla Sofía Gascón just became the first out trans actor to score an Oscar nomination

By / / Good News For Humankind

Karla Sofía Gascón just became the first openly transgender person ever nominated for an acting Oscar, earning a best actress nod for her leading role in Emilia Pérez. The French-Spanish musical swept up 13 nominations in total, falling just one shy of the all-time record. Gascón, who transitioned in 2018, plays a cartel boss building a new life after her own transition — a role she fought for and says she could only have brought this depth to later in life. Her nomination won’t fix Hollywood’s long gap in trans representation overnight, but it cracks open a door that was firmly shut, signaling to studios and audiences alike that trans stories told with authenticity belong at the center of the screen.

New York, for article on NYC offshore wind farm

New York City to get a $3 billion, 80,000-acre offshore wind farm

By / / Good News For Humankind

Offshore wind is coming to New York City for the first time, with Empire Wind 1 set to power roughly half a million residents by 2027. Developed by Equinor and backed by a $3 billion financing package, the 810 MW project will be the first to plug directly into the city’s grid — covering about 6% of NYC’s electricity needs. Construction will run through a redeveloped South Brooklyn Marine Terminal, creating more than 1,000 union jobs along the waterfront. It’s not a silver bullet, but it’s a working proof of concept: the largest U.S. city now has a real, physical link to clean ocean wind, and a template other coastal cities can follow.

Offshore oil rig at sunset, for article on offshore drilling ban

Biden permanently bans offshore drilling in 625 million acres of ocean

By / / Good News For Humankind

Offshore drilling is now off the table across 625 million acres of U.S. coastal waters, thanks to a sweeping executive action from President Biden. The protections cover the entire East Coast, the eastern Gulf of Mexico, the Pacific shores of Washington, Oregon, and California, and parts of Alaska’s Northern Bering Sea. What makes this move different is its staying power: Biden invoked a 1953 law that legal experts say can’t easily be undone without Congress. Alongside the ocean announcement, two new national monuments in California — both championed by Native tribes — bring his total conserved lands to 10. It’s a quiet but powerful reminder that some places are simply too precious to drill, and that lasting protection is possible when law, science, and community all pull in the same direction.

Depiction of intestines, for article on dostarlimab FDA breakthrough designation, for article on dostarlimab FDA Breakthrough Designation

“100% successful” cancer drug gets landmark U.S. FDA approval

By / / Good News For Humankind

A cancer drug called dostarlimab just earned the FDA’s Breakthrough Therapy Designation after eliminating rectal tumors in all 42 patients who completed a Memorial Sloan Kettering trial — with some participants now cancer-free for up to four years. The drug works by helping the immune system recognize and attack tumors carrying a specific genetic signature, sparing patients the surgery, radiation, and chemotherapy that often leave lasting damage to fertility, bowel function, and quality of life. Side effects have been mild, and the new designation could shave years off the path to wider availability. For the roughly 46,220 Americans diagnosed with rectal cancer each year, this hints at a future where beating the disease no longer means trading one kind of suffering for another.

International court rules against El Salvador in key abortion rights case

By / / Good News For Humankind

The Inter-American Court of Human Rights just set a new floor for reproductive rights across Latin America, ruling that El Salvador violated a young woman’s fundamental rights by denying her a life-saving abortion in 2013. Beatriz was 22, gravely ill with lupus and kidney damage, and carrying a fetus that could not survive outside the womb — yet the country’s total ban forced her into an emergency C-section instead of care. The court has now ordered El Salvador to allow abortions when a woman’s life or health is at risk. Six other Latin American countries still ban abortion outright, and advocates say Beatriz’s name now anchors a precedent they’ll carry into courts and legislatures across the hemisphere.